

CURRICULUM VITAE

Name: Timothy Ryan Donahue, MD, FACS

Address: 10833 Le Conte Avenue
14-174 Center for the Health Sciences
Los Angeles, CA 90095-7074
Phone: 310-206-7440
FAX: 310-825-9565
E-mail: tdonahue@mednet.ucla.edu

Education: Undergraduate: BA, Northwestern University, Evanston IL,
6/1998
Medical: MD, Northwestern University, Chicago IL,
5/2002
Residency: UCLA Medical Center, Department of Surgery,
6/2002 – 6/2009

Licensure: California, A86040

Board Certification:
American Board of Surgery, 2010

Professional Experience:
Assistant Professor of Surgery, and Molecular and Medical Pharmacology,
David Geffen School of Medicine at UCLA, 7/2009 – 6/2015
Director, Surgical Oncology Service, UCLA Medical Center, 2013 – present
Director, Core Surgery Residency Program, UCLA Department of Surgery,
2013 – 6/2015
Associate Director, General Surgery Residency Program, UCLA
Department of Surgery, 6/2013 – 6/2015
Program Director, General Surgery Residency Program, UCLA Department
of Surgery, 7/2015 - present
Chief, Section of Gastrointestinal and Pancreas Surgery, Division of General
Surgery, Department of Surgery, UCLA, 7/2014 – 7/2017
Associate Professor (with tenure) of Surgery, and Molecular and Medical
Pharmacology, David Geffen School of Medicine at UCLA, 7/2015 –
7/2018
Chief, Division of Surgical Oncology, Department of Surgery, UCLA,
7/2017 – present
Vice Chair, Surgical Cancer Care, Department of Surgery, UCLA, 7/2017 –
present
Professor (with tenure) of Surgery, and Molecular and Medical
Pharmacology, David Geffen School of Medicine at UCLA, 7/2018 -
present

Professional Activities:

Professional association memberships: American Association for Cancer Research, American College of Surgeons, American Medical Association, Pancreas Club, American Hepato-Pancreato-Biliary Association, Association for Academic Surgery, Society of Surgical Oncology, Pacific Coast Surgical Association, Society of University Surgeons, American Program Directors Society, Surgical Society of the Alimentary Tract.

Professional association committee service:

Association for Academic Surgery, Membership Committee member, 2013 – 2015

American College of Surgeons, Surgical Research Committee member, 2014 – 2017

Society of University Surgeons, Executive Council, Scholarship Committee Chair, 2015 – present

American College of Surgeons, Surgical Research Committee Executive Member, 2017 – present

NCI/NIH F09B Study Section, Standing Member, 2016 – present

NCI/NIH SPORE Program for Gastrointestinal Cancers Review Panel, ad hoc Member, 2017 – present

UCLA Committee Service:

UCLA Academic Senate Legislative Assembly, Surgery Department Representative, 2013 – 2015

UCLA Jonsson Comprehensive Cancer Center, Internal Scientific Peer Review Committee member, 2015 – present

Head, General Surgery Residency Program Competency Committee, 2014 – 2015

Head, Division of General Surgery Finance Committee, 12/2015 – 7/2017

UCLA Jonsson Comprehensive Cancer Center, Policy Committee, 12/2017 - present

David Geffen School of Medicine, Council on Cancer, 1/2018 - present

Editorial services:

Numerous (ad hoc reviewer)

Case Reports in Pancreatic Cancer (associate editor)

Journal of Gastrointestinal Surgery (editorial board member)

Honors and Special Awards:

Outstanding Medical Student Teaching Award, UCLA, 2005

Outstanding Medical Student Teaching Award, UCLA, 2006

ASCO Foundation Merit Award. 2008

Most Outstanding Vascular Surgery Chief Resident, 2008

Most Outstanding Chief Resident Medical Student Teaching Award, 2009

NIH Loan Repayment Program (LRP), 2010 – 2012

NIH LRP Renewal, 2012 – 2013

NIH LRP Renewal, 2013 – 2014
NIH LRP Renewal, 2014 – 2015
NIH LRP Renewal, 2015 – 2016
NIH LRP Renewal, 2016 – 2017
Golden Scalpel Award, Most Outstanding Teaching, Professor, 2017-2018

Research Grants and Fellowships Received:

1. Hirshberg Foundation Seed Grant

Donahue (PI) 11/01/09-10/31/10 \$50,000/yr

Identifying the Malignant Signatures Associated with the Development of Human Pancreatic Cancer

The major goals of this project are to perform an expression- and single nucleotide polymorphism array of human pancreatic cancer to identify gene/expression changes associated with pancreatic cancer and link them with prognosis.

Role: PI

2. UCLA Department of Surgery Startup Funding

Donahue (PI) 1/1/10-12/31/12 \$150,000/yr

3. Molecular Analysis of Pancreatic Cancer

Role: PI

4. IMED Seed Grant

Donahue (PI) 7/1/2009-6/30/2010 \$108,000/yr

To conduct an integrative survival-based pancreatic cancer array analysis, including SNP, mRNA, and miRNA arrays of 50 surgically resected pancreatic cancer samples.

Role: PI

5. IMED Collaborative Research Funding Initiative

Donahue (PI) 4/1/2010 – 4/1/2011 \$50,000/yr

Influence of the Src pathway on pancreatic cancer progression

The major goals of this project are to determine the functional significance of key nodes within the Src signaling pathway that are associated with poor prognosis in patients with pancreatic cancer and to leverage them against the UCLA Src inhibitor Phase II clinical trial.

Role PI

6. Translational Acceleration Grant (Cal Tech&UCLA)

Dubinett (PI) 4/1/2010 – 4/1/2011 \$100,000/yr

Genetic Analysis of Circulating Tumor Cells in Lung and Pancreatic Cancer

The major goals of this project are to monitor circulating tumor cells (CTC) in the perioperative period using UHG-MACS technology and to assess the surface and intracellular markers of CTCs via on-chip staining.

Role: Co-investigator

7. UCLA Scholars in Translational Medicine Program

Donahue (PI) 5/1/2010 – 5/1/2013 \$50,000/yr

The Regulation of Malignant Signatures in Pancreatic Cancer Stem Cells

8/2018

The major goals of this project are to determine the miRNA signature of pancreatic cancer and test their roles on PTEN expression in pancreatic cancer stem cells.

Role: PI.

8. Association for Academic Surgery – Joel Roslyn Award

Donahue (PI) 10/1/2011 – 9/29/2013 \$35,000/yr

The influence of SRC signaling on human pancreatic cancer progression

Role: PI

9. California Research Coordinating Committee

Donahue (PI) 7/1/2011 – 6/31/2012 \$50,000/yr

The influence of SRC signaling on human pancreatic cancer progression

Role: PI

10. Gerald Oppenheimer Foundation Clinical Translational Seed Grant

Donahue (PI) 4/1/2011 – 3/31/2012 \$35,000/yr

The influence of SRC signaling on human pancreatic cancer progression

Role: PI

11. UC Faculty Research Grant

Donahue (PI) 1/2011 – 12/2011 \$15,000/yr

MicroRNA regulation of AKT signaling in human pancreatic cancer

Role: PI

12. Riley Foundation

Donahue (PI) 1/1/2012 – 12/31/2012 \$150,000/yr

The impact of cytotoxic chemotherapy on stromal biology in pancreatic cancer

Role: PI

13. Concern Foundation

Donahue (PI) 7/1/2012 – 6/31/2015 \$50,000/yr

Targeting the immunosuppressive activity of MDSCs in pancreatic cancer

Role: PI

14. CURE: Pilot and Feasibility Study

Donahue (PI) 1/1/2012 – 12/30/2012 \$35,000/yr

A comprehensive analysis of pancreatic cyst fluid miRNA for earlier cancer diagnosis

Role: PI

15. Clinical and Translational Science Institute

Donahue (PI) 1/1/2012 – 12/31/2012 \$10,000/yr

Targeting the chemotherapy-resistant epigenetic reprogramming of stromal cells in human pancreatic cancer

Role: PI

8/2018

16. STOP Cancer Career Development Award

The molecular genetics of human pancreatic cancer

Donahue (PI) 1/1/2012 – 12/31/2014 \$50,000/yr

Role: PI

17. JCCC Foundation Seed Grant

Targeting Ubiquitin Ligase CBL Mediated Chemoresistance in Pancreatic Cancer

Donahue (PI) 7/1/2013 – 6/31/2014 \$50,000/yr

Role: PI

18. JCCC Foundation Impact Grant

Epigenetic Integration of Growth Signals and Resistance via the Stromal
Microenvironment in Pancreatic Cancer

Kurdistani, Donahue, Dawson (multi-PI)
10/1/2013 – 9/29/2014 \$200K/yr

Role: co-PI

19. Canary Foundation

Targeting the immunosuppressive activity of MDSCs in pancreatic cancer

Donahue (PI) 9/1/2014 – 8/31/2015 \$50K/yr

20. NCI/NIH

PET imaging-guided Personalized Therapy in Pancreatic Cancer – R01 CA187678

Radu, Donahue, Czernin (multi-PI)
7/1/2014 – 6/31/2019 \$336,764/yr

Role: co-PI

21. Department of Energy

UCLA Translational Biomarker Development Program (UTBD)

Czernin (PI) 9/1/2014 – 8/31/2016 \$1M/year

Role: co-Investigator

22. NCI/NIH

UCLA Multifunctional Mesoporous Silica Nanoparticle Platform for Treatment of
Pancreas Cancer – U01 CA198846

Nel, Donahue, et al. (multi-PI)
9/25/2015 – 7/31/2020 \$513,147/yr

Role: co-PI

23. W.M. Keck Foundation

Leveraging metabolic vulnerabilities to enhance replication stress in KRAS driven cancers

Donahue, Radu (multi- PI) 7/1/2016 – 6/30/2018 \$500,000 (Direct)/yr

Role: co-PI

24. NCI/NIH

Multifunctional immunoPET tracers for pancreatic and prostate cancer

Wu, Reiter (multi-PI) 8/01/2016 – 7/31/2021 \$288,426 (Direct)/yr
Role: co-Investigator

Research Grants and Fellowships Pending:

1. Novel Modulators of Nucleotide Pools and Replication Stress in Pancreatic Cancer
Donahue, Radu (multi-PI) 06/01/2018 – 5/31/2023 \$486,329 (Direct)/yr
Role: PI (contact)
2. Elucidating Mechanisms of Effectiveness and Resistance to Somatostatin
Receptor Targeted Radioligand Therapy Using ¹⁷⁷Lu-DOTATATE
Czernin, Radu, Donahue (multi-PI)
02/01/2018-01/31/2022 \$272,727 (Direct)/yr
Role: co-PI

Trainees:

Graduate Students

PhD Dissertation Committees

1. Katie Kershaw, (2014 - present)
Dissertation Committee
Mentor: David Dawson, MD, PhD
2. Angelyn Nguyen, (2015 - 2017)
Dissertation Committee
Mentor: Amy Rowat, PhD
3. Evan Abt, (2015 - present)
Dissertation Committee
Mentor: Caius Radu, MD
4. Soumya Poddar, (2015 - present)
Dissertation Committee
Mentor: Caius Radu, MD

Postdoctoral Fellows (direct mentor)

1. Brian Kadera, MD
2011 – 2013
Current position: Assistant Professor, UCLA
2. Paul Toste, MD
2012 – 2014
Current position: Thoracic Fellow, Brigham and Women's Hospital

3. Andrew Nguyen, MD
2013 – 2015
Current position: Surgical Oncology Fellow, City of Hope Cancer Center
4. Sanjeet Patel, MD, PhD
2014 – 2017
Current position: Cardiac Surgery Resident, USC
5. Jennifer Williams, MD
2014 – 2016
Current position: Senior Resident, Harbor UCLA
6. Irmina Gawlas, MD
2015 – 2017
Current position: Senior Resident, UCLA
7. Amanda Maas, MD
2016 – Present
Current position: Senior Resident, UCLA
8. Stephanie Kim, MD
2017 – Present
Current position: ongoing
9. Shili Xu, PhD
2018 – Present
Current position: ongoing
10. Lei Zhou, MD
2018 – Present
Current position: ongoing
11. Alex Moore, MD
2018 – Present
Current position: ongoing

Lectures and Presentations:

- 1) “Laparoscopic solid organ surgery,” Kern County Medical Center, Bakersfield CA, 11/2009
- 2) “Impact of splenectomy on thrombocytopenia, chemotherapy, and survival in patients with unresectable pancreatic cancer,” Western Surgical Association, San Antonio TX, 11/2009
- 3) “Downstaging chemotherapy may alter the classic CT/MRI signs of vascular involvement in patients with pancreaticobiliary cancers. This should influence patient selection for surgery,” Pacific Coast Surgical Association, Maui HI, 2/2010

- 4) "Downstaging chemotherapy may alter the classic CT/MRI signs of vascular involvement in patients with pancreaticobiliary cancers. This should influence patient selection for surgery," Pancreas Club, New Orleans LA, 5/2010
- 5) "Pancreatic cyst fluid microRNA-21 and -221 are associated with invasive cancer," Pancreas Club, Chicago IL, 5/6/2011
- 6) "Pancreatic cancer: a surgeon-scientist's perspective," Community Medical Center Grand Rounds, Ventura CA, 8/30/2011
- 7) "Acute pancreatitis," Los Robles Medical Center Grand Rounds, Thousand Oaks CA, 3/2/2012
- 8) "Pancreatic cancer: a surgeon-scientist's perspective," Holy Cross Medical Center Grand Rounds, Mission Hills CA, 7/13/2012
- 9) "Targeting microRNA regulated ecosystems in human pancreatic cancer," University of California San Francisco Pancreatic Cancer Center Retreat, San Francisco CA, 5/24/2012
- 10) "Pancreatic cancer: recent progress and future challenges," UCLA Department of Surgery Grand Rounds, Los Angeles CA, 8/8/2012
- 11) "Acute pancreatitis," Saint Joseph Medical Center, Orange CA, 8/10/2012
- 12) "Biomarkers and Genetic Determinants of Disease," Session Moderator: American College of Surgeons Clinical Congress, Chicago IL, 10/2/2012
- 13) "Targeting the Pancreatic Cancer Stroma," Society of Clinical Surgery, Los Angeles, CA, 11/2/2012
- 14) "Pancreatic Cancer 2012: Surgical and Medical Treatment," Insights into Cancer, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA, 11/13/2012
- 15) "MicroRNA for Earlier Pancreatic Cancer Diagnosis," Canary Foundation for Early Cancer Detection Annual Meeting, Seattle WA, July 2013.
- 16) "Translational PET Imaging to Guide Chemotherapy in Human Pancreatic Cancer," Science of Pancreatic Cancer Study Group, Cold Spring Harbor (CSH), CSH, NY, 9/28/2013.
- 17) "Targeting Pancreatic Cancer Chemoresistance," Grand Rounds, Department of Surgery, UCLA, Los Angeles, CA, 11/20/2013.
- 18) "AAS-2011 Joel J. Roslyn MD Faculty Research Award Progress Report," Academic Surgical Congress, San Diego, CA, 2/6/2014.
- 19) "Targeting the Senescence-Associated Secretory Phenotype (SASP) of Pancreatic Cancer Fibroblasts," CURE Annual Symposium, UCLA, Los Angeles, CA, 3/14/2014
- 20) "Do All Nonfunctional & Localized Pancreatic Neuroendocrine Tumors (PNETs) Need to Be Surgically Resected?" The International Hepatopancreatobiliary Surgery Forum, Second Affiliated Hospital Zhejiang University, China, 6/8/2014
- 21) "Chronic Pancreatitis 2014: An Update," UCLA Department of Surgery Grand Rounds, UCLA, Los Angeles, CA, 11/26/2014
- 22) "Hypothesis and Specific Aims," Academic Surgical Congress, Surgical Investigators Course, Las Vegas, NV, 2/2/2015
- 23) "Surgical Management of Pancreatic Cancer: 2015," 11th Annual Agi Hirshberg Symposium on Pancreatic Cancer, Los Angeles, CA, 2/28/2015.
- 24) "Management of Chronic Pancreatitis," UCLA Primary Care Update 2015, Las Vegas, NV, 4/17/2015

- 25) “An Integrated Practice Unit for Patients with Pancreatic Cancer at UCLA,” 12th Annual Agi Hirshberg Symposium on Pancreatic Cancer, Los Angeles, CA, 3/5/2016
- 26) “Pancreas Cancer in 2016: A Surgeon’s Perspective,” 4th Annual UCLA-Mellinkoff Gastroenterology and Hepatology Symposium, Los Angeles, CA, 3/12/2016
- 27) “Autophagy Inhibition Sensitizes Kras-driven Pancreatic Cancer Cells to Replication Stress” Surgical Biology Club I, Washington DC, 10/9/2016.
- 28) “Surgeon’s perspective: resectability vs. resection in locally advanced pancreatic cancer following neo-adjuvat therapy; how to objectivize resection decision in clinical trials,” FibroGEN Pancreatic Cancer Advisory Board, San Francisco CA, 11/30/2016
- 29) “Pancreatic Cancer: Diagnosis and Management, 2017” UCLA Primary Care Update, Las Vegas NV, 4/7/2017.
- 30) “The Core Mission of Academic Surgery: *To Change the Standard of Care*” UCLA Department of Surgery Grand Rounds, Los Angeles, CA, 5/17/2017.
- 31) “Surgery of Pancreatic Cancer” American Pancreatic Association Annual Meeting, San Diego, CA, 11/8/2017.
- 32) “Identification of new modulators of replication stress and nucleotide metabolism in pancreatic cancer” UCLA Jonsson Comprehensive Cancer Center Signal Transduction Area Annual Meeting Keynote Address, 12/13/2017
- 33) “Treatment of Gastroenteropancreatic Neuroendocrine Tumors: *A Multi-disciplinary Approach*” Department of Surgery Grand Rounds, Los Angeles, CA, 12/6/2017.
- 34) “Update on Pancreatic Surgery” American College of Surgeons Southern California Chapter, Annual Meeting, Santa Barbara, CA, 1/19/2018.
- 35) “UCLA Pancreatic Cancer Program,” UC Pancreatic Cancer Consortium Planning Meeting, San Diego, CA, 2/10/2018.
- 36) “UCLA Pancreatic Cancer Program,” Annual Agi Hirshberg Symposium on Pancreatic Cancer, Los Angeles, CA, 3/10/2018
- 37) “Surgery for Pancreatic Neuroendocrine Tumors,” Annual Los Angeles County Neuroendocrine Tumor Society Meeting, Los Angeles, CA, 5/19/2018.
- 38) “Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion,” UCLA Metabolism Theme Grand Rounds, Los Angeles, CA, 5/24/2018.
- 39) “Surgery for Pancreatic Neuroendocrine Tumors,” North American Neuroendocrine Tumor Society, Regional Meeting, Los Angeles, CA, 6/9/2018.

Publications/Bibliography:

Research Papers (Peer-reviewed):

A. Research Papers

1. DiSciullo, G., **Donahue, T.**, Bogen, S., “L1 is Required for Lymph Node Reticular Matrix Development,” *Journal of Experimental Medicine*, 187(12): 1953 – 63, 1998.

2. Ribas, A., Comin-Andiux, B., Economou, J.S., **Donahue, T.R.**, De La Rocha, P., Morris, L.F., Jalil, J., Dissette, V.B., Shintaku, T.B., Glaspy, J.A., Gomez-Navarro, J, Cochran, A., “Intratumoral Immune Cell Infiltrates, FoxP3, and Indoleamine 2,3-dioxygenase (IDO) in Patients with Melanoma Undergoing CTLA4 Blockade.” *Clinical Cancer Research*, 15(1): 390-9, 2009.
3. Vo, D.D., Prins R.M., Wang, E., **Donahue, T.R.**, Begley J.L., Morris, L.F., Bruhn, K.W., de la Rocha, P., Yang M.,Y., Mok, S., Garban, H.J., Craft, N., Economou, J.S., Marincola, F., Ribas, A., “Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824.” *Cancer Research*, 69(22): 8693-9, 2009.
4. **Donahue, T.R.**, Kazanjian, K.K., Isacoff, W.H., Reber, H.A., Hines, O.J., “Impact of Palliative Splenectomy on Thrombocytopenia, Administration of Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer.” *J Gastrointest Surg*. 14(6):1012-8, 2010.
5. **Donahue, T.R.**, Kattan M.W., Nelson S.D., Tap W.D., Eilber F.R., Eilber, F.C., “Impact of Neoadjuvant Treatment on Histopathologic Response and Survival in Patients with Primary High-Grade Retroperitoneal Soft Tissue Sarcomas.” *Cancer* 116(16):3883-91, 2010.
6. **Donahue, T.R.**, Reber, H.A., Farrell, J.J., Tomlinson, J.S., Eibl, G., Hines, O.J., “Cystic Neoplasms of the Pancreas: Results of 123 Cases.” *Pancreas* 39(8): 1271-6, 2010.
7. Hill, R., Calvopina, J.H., Kim, C., Wang, Y., Dawson, D.W., **Donahue, T.R.**, Dry, S., Wu, H., “PTEN Loss Accelerates KrasG12D-Induced Pancreatic Cancer Development.” *Cancer Res*, 70(18):7114-7125, 2010.
8. **Donahue, T.R.**, Isacoff, W.H., Hines, O.J., Tomlinson J.S., Farrell, J.J., Bhat, Y.M., Garon, E., Clerkin, B.M., Reber, H.A., “Downstaging Chemotherapy (DCTx) May Alter the Classic CT/MRI Signs of Vascular Involvement in Patients with Pancreaticobiliary Cancers. This Should Influence Patient Selection for Surgery.” *Archives of Surgery*, 146(7):836-43, 2011.
9. Quatramoni, J., Morris, L.F., **Donahue, T.R.**, Wang, Y., Chatila T., Economou, J.S., “T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express FoxP3,” *J. Hematol. Oncol.*, 23(4):48, 2011.
10. **Donahue, T.R.**, Tran, L.M., Hill, R., Li, Y., Kovoichich, A., Calvopina J.H., Patel, S.G., Wu, N., Hindoyan A., Farrell, J.J., Li, X., Dawson, D.W., Wu, H., “Integrative survival-based molecular profiling of human pancreatic cancer,” *Clin Cancer Research*, 18(5):1352-63, 2012.
11. Hill, R., Li, Y., Tran, L.M., Dry, S., Hargan Calvopina, J., Garcia, A.J., Kim, C., Wang, Y., **Donahue, T.R.**, Herschman, H.R., Wu, H., “Cell intrinsic role of Cox-2 in pancreatic cancer development,” *Mol Cancer Ther*, 11(10):2127-37, 2012.
12. Nguyen Kovoichich A, Arensman M, Lay AR, Rao NP, **Donahue TR**, Li X, French SW, Dawson DW, “HOXB7 promotes invasion and predicts survival in pancreatic adenocarcinoma,” *Cancer*, 119(3):529-39, 2013.
13. Wei CH, Gorgan TR, Elashoff DA, Hines OJ, Farrell JJ, **Donahue TR**, “A meta-analysis of gemcitabine biomarkers in patients with pancreatobiliary cancers,” *Pancreas*, 42(8):1303-10, 2013.

14. Arensman MD, Kovoichich AN, Kulikauskas RM, Lay AR, Yang PT, Li X, **Donahue TR**, Major MB, Moon RT, Chien AJ, Dawson DW, “WNT7B mediates autocrine Wnt/ β -catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma,” *Oncogene*, 33(7):899-908, 2013.
15. Donald G, **Donahue TR**, Reber HA, Hines OJ, “The evolving management of infected pancreatic necrosis,” *Am Surg*, 78(10):1151-5, 2013.
16. Donald G, Sunjaya D, **Donahue TR**, Hines OJ, “Polyp on ultrasound: now what? The association between gallbladder polyps and cancer,” *Am Surg*, 79(10): 1005-8, 2013.
17. Donald GW, Sunjaya D, Lu X, Chen F, Clerkin B, Eibl G, Li G, Tomlison JS, **Donahue, T.R.**, Reber HA, Hines OJ, “Perioperative antibiotics for surgical site infection in pancreaticoduodenectomy: Does the SCIP-approved regimen provide adequate coverage?” *Surgery*; 2013 Aug;154(2):190-6.
18. Farrell JJ, Toste PM, Wu N, Li L, Li X, Lin TM, Wong J, Wu X, Dawson DW, Wu H, **Donahue TR**, “Endoscopically acquired pancreatic cyst fluid microRNA 21 and 221 are associated with invasive cancer,” *American Journal of Gastroenterology*, 2013 Aug;108(8):1352-9.
19. Kadera BE, Li L, Toste PA, Wu N, Adams C, Dawson DW, **Donahue T.R.**, “MicroRNA-21 in Pancreatic Ductal Adenocarcinoma Tumor-Associated Fibroblasts Promotes Metastasis,” *PLoS One*, 2013, Aug 22;8(8).
20. Rochefort MM, Ankeny JS, Kadera BE, Donald GW, Isacoff W, Wainberg ZA, Hines OJ, **Donahue TR**, Reber HA, Tomlinson JS, “Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system,” *Ann Surg Oncol*, 20(13):4322-9, 2013
21. Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, “Nonfunctional pancreatic neuroendocrine tumors < 2 cm on preoperative imaging are associated with a low incidence of nodal metastases and an excellent overall survival.” *J Gastrointest Surgery*, 17(12):2105-13, 2013.
22. Kadera BE, Sunjaya DB, Isacoff WH, Li L, Hines OJ, Tomlinson JS, Dawson DW, Rochefort MM, Donald GW, Clerkin BM, Reber HA, **Donahue, T.R.**, “Locally advanced pancreatic cancer: prolonged preoperative treatment is associated with lymph node negativity and excellent overall survival.” *JAMA Surg*, 149(2):145-53, 2014.
23. Wagner JP, Chen DC, **Donahue TR**, Quach C, Joe Hines O, Hiatt JR, Tillou A, “Assessment of resident operative performance using a real-time mobile Web system, preparing for the milestone age.” *J Surg Educ*, 71(6):e41-6, 2014.
24. Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, **Donahue TR**, Dawson DW, “The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth.” *Mol Cancer Ther.*, 13(10):2303-14, 2014.
25. Farrell JJ, Nguyen AH, Li L, Taitshev S, Toste P, Dawson DW, **Donahue TR**, “Stromal MicroRNA-21 Levels Predict Response to 5-Fluorouracil in Patients with Pancreatic Cancer.” *J. Surg. Onc.*, 110(8):952-9, 2014.
26. Sherman MH, Yu RT, Engle DD, Ding N, Atkins AR, Tiriach H, Collisson EA, Connor F, Van Dyke T, Kozlov S, Martin P, Tseng TW, Dawson DW, **Donahue TR**, Masamune A, Shirmosegawa T, Apte MV, Wilson JS, Ng B, Lau SL, Gunton

- JE, Wahl GM, Hunter T, Drebin JA, O'Dwyer PJ, Liddle C, Tuveson DA, Downes M, Evans RM, "Vitamin d receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy." *Cell*, 159(1):80-93, 2014.
27. Nguyen D, Dawson DW, Hines OJ, Reber HA, **Donahue TR**, "Mucinous cystic neoplasms (MCNs) of the pancreas: are we overestimating malignant potential?" *Am Surg.*, 89(10):915-9, 2014.
 28. Kadera BE, Toste PA, Wu N, Li L, Dawson DW, **Donahue TR**, "Low Expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and is Targeted by Epidermal Growth Factor Receptor Inhibition," *Clin Cancer Res.*, 21(1): 157 – 65, 2015.
 29. Nguyen AH, Toste P, Farrell JJ, Clerkin BM, Muthusamy VR, Watson R, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, "Current Indications for Surgery of Intraductal Papillary Mucinous Neoplasms May Overlook Some Patients with Cancer: Recommendations for Change," *J. Gastrointest Surg.*, 19(2): 258 – 65, 2015.
 30. Ge PS, Hamerski CM, Watson RR, Komanduri S, Cinnor BB, Bidari K, Klapman JB, Lin CL, Shah JN, Wani S, **Donahue TR**, Muthusamy VR, "Plastic biliary stent patency in patients with locally advanced pancreatic adenocarcinoma receiving downstaging chemotherapy," *Gastrointest. Endosc.* 81 (2): 360-6, 2015
 31. Toste PA, Li L, Kadera BE, Nguyen AH, Tran LM, Wu N, Madnick DL, Patel SG, Dawson DW, **Donahue TR**, "P85 α is a miR target and affects chemosensitivity in pancreatic cancer," *J Surg Res*, 196(2):285-93, 2015.
 32. Thompson M, Dawson DW, **Donahue TR**, Pellegrini M, "Pancreatic Cancer Patient Survival Correlates with DNA Methylation of Pancreas," *PLoS One*, Jun 3; 10(6):e0128814, 2015
 33. Gaddam S, Ge PS, Keach JW, Mullady D, Fukami N, Edmundowicz SA, Azar RR, Shah RJ, Murad FM, Kushir VM, Watson RR, Ghassemi KF, Sedarat A, Komanduri S, Jaiyeola DM, Brauer BC, Yen RD, Amateau SK, Hosford L, Hollander T, **Donahue TR**, Schulick RD, Edil BH, McCarter M, Gajdos C, Attwell A, Muthusamy VR, Early DS, Wani S, "Suboptimal accuracy of carcinoembryonic antigen in differentiation of mucinous and nonmucinous pancreatic cysts: results of a large multicenter study," *Gastrointest Endosc* 82(6), 1060-9, 2015.
 34. Ge PS, Gaddam S, Keach JW, Mullady D, Fukami N, Edmundowicz SA, Azar RR, Shah RJ, Murad FM, Kushir VM, Ghassemi KF, Sedarat A, Watson RR, Amateau SK, Brauer BC, Yen RD, Hosford L, Hollander T, **Donahue TR**, Schulick RD, Edil BH, McCarter MD, Gajdos C, Attwell AR, Muthusamy VR, Early DS, Wani S, "Predictors for Surgical Referral in Patients with Pancreatic Cystic Lesions Undergoing Endoscopic Ultrasound: Results from a Large Multicenter Cohort Study," *Pancreas*, 45(1), 51-7, 2016.
 35. Williams JL, Nguyen AH, Rochefort M, Muthusamy VE, Wainberg ZA, Dawson DW, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, "Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease," *J Surg Onc*, 112(4):396-402, 2015.
 36. Stark AP, Sacks GD, Rochefort MM, **Donahue TR**, Reber HA, Tomlinson JS, Dawson DW, Eibl G, Hines OJ, "Long-term survival in patients with pancreatic ductal adenocarcinoma," *Surgery*, 159(6): 1520-7, 2016.

37. Gifford JB, Huang W, Zeleniak AE, Hindoyan A, Wu H, **Donahue TR**, Hill R, “Expression of GRP78, Master Regulator Of The Unfolded, Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma,” *Mol Cancer Ther*, 15(5): 1043-52, 2016.
38. Toste PA, Nguyen AH, Kadera BE, Duong M, Wu N, Gawlas I, Tran LM, Bikhchandani M, Li L, Patel SG, Dawson DW, **Donahue TR**, “Chemotherapy-induced Inflammatory Gene Signature and Pro-tumorigenic Phenotype in Pancreatic CAFs via Stress-associated MAPK,” *Mol Cancer Res*, 14(5): 437-47, 2016.
39. Kim W, Le TM, Wei L, Poddar S, Bazzi J, Wang X, Uong NT, Abt ER, Capri JR, Austin WR, Van Valkenburgh JS, Steele D, Gipson RM, Slavik R, Cabebe AE, Taechariyakul T, Yaghoubu SS, Lee JT, Sadeghi S, Lavie A, Faull KF, Witte ON, **Donahue TR**, Phelps ME, Herschman HR, Herrmann K, Czernin J, Radu CG, “[18F]CFA as a clinically translatable probe for PET imaging of deoxycytidine kinase activity,” *Proc Natl Acad Sci U.S.A.*, 113(15): 4027-32, 2016
40. Moris M, Dawson DW, Jiang J, Lewis J, Nassar A, Takeuchi KK, Lay AR, Zhai Q, **Donahue TR**, Kelly KA, Crawford HC, Wallace M, “Plectin-1 as a Biomarker of Malignant Progression in Intraductal Papillary Mucinous Neoplasms: A Multicenter Study,” *Pancreas*, 45(9):1353-8, 2016.
41. Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Wainberg ZA, Hines OJ, Reber HA, **Donahue TR**, “CA19-9 Normalization During Pre-operative Treatment Predicts Longer Survival for Patients with Locally Progressed Pancreatic Cancer,” *J Gastrointest Surg*. 20(7):1331-42, 2016.
42. Vorvis C, Hatziapostolou M, Mahurkar-Joshi S, Koutsioumpa M, Williams J, **Donahue TR**, Poultides GA, Eibl G, Iliopoulos D, “Transcriptomic and CRISPR/Cas9 technologies reveal FOXA2 as a tumor suppressor gene in pancreatic cancer,” *Am J Physiol Gastrointest Liver Physiol.*, 310(11):G1124 – 37, 2016.
43. Ankeny JS, Court CM, Hou S, Li Q, Song M, Wu D, Chen JF, Lee T, Lin M, Sho S, Rochefort MM, Girgis MD, Yao J, Wainberg ZA, Muthusamy VR, Watson RR, **Donahue TR**, Hines OJ, Reber HA, Graeber TG, Tseng HR, Tomlinson JS, “Circulating tumor cells as a biomarker for diagnosis and staging in pancreatic cancer,” *Br J Cancer*, 114(12): 1367-75, 2016.
44. Williams JL, Chan CK, Toste PA, Gawlas IA, Vasquez CR, Sunjaya DB, Swanson E, Koo J, Hines OJ, Reber HA, Dawson DW, **Donahue TR**, “Periampullary Cancers: Histologic Subtype is a Stronger Determinant of Patient Survival than Anatomic Location,” *JAMA Surgery*, 152(1): 82-88, 2017.
45. Nguyen AV, Nyberg KD, Scott MB, Welsh AM, Nguyen AH, Wu N, Hohlbauch SV, Geisse NA, Gibb EA, Robertson AG, **Donahue TR**, Rowat AC, “Stiffness of pancreatic cancer cells is associated with increased invasive potential,” *Integr Biol (Camb)*., 8(12): 1232 – 1245, 2016.
46. Sugimoto M, Elliot IA, Nguyen AH, Kim S, Muthusamy VR, Watson R, Hines OJ, Dawson DW, Reber HA, **Donahue TR**, “Current Recommendations for Surveillance or Surgery Based on Main Pancreatic Duct Size May Overlook Cancer in Intraductal Papillary Mucinous Neoplasms,” *JAMA Surgery*, 152(1), 2017.
47. Nguyen AH, Matsuyama C, Wu N, Vogelauer M, Attar N, Elliott IA, Ghukasyan R, Toste PA, Patel SG, Williams JL, Li L, Dawson DW, Radu CG, Kurdistani SK,

- Donahue TR**, “Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts,” *Oncotarget* 8(12): 19074-19088, 2017.
48. Ge PS, Muthusamy VR, Gaddam S, Jaiyeola DM, Kim S, Sedarat A, **Donahue TR**, Hosford L, Wilson RH, Grande DP, Keswani RN, Kushnir VM, Mullady D, Edmundowicz SA, Early DS, Komanduri S, Wani S, Watson RR, “Evaluation of the 2015 AGA guidelines on pancreatic cystic neoplasms in a large surgically confirmed multicenter cohort,” *Endosc Int Open*, 5(3):e201-e208, 2017.
 49. Elliott IA, Chan C, Russell TA, Dann AM, Williams JL, Damato L, Chung H, Girgis MD, Hines OJ, Reber HA, **Donahue TR**, “Distinction of Risk Factors for Superficial vs. Organ-Space Surgical Site Infections After Pancreatic Surgery,” *JAMA Surg.* 152(11): 1023-1029, 2017.
 50. Liu X, Lin P, Perrett I, Lin J, Liao YP, Chang CH, Jiang J, Wu N, **Donahue T**, Wainberg Z, Nel AE, Meng H, “Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer,” *J Clinical Investigation*, 127(5):2007-2018, 2017.
 51. Schwed AC, Lee SL, Salcedo ES, Reeves ME, Inaba K, Sidwell RA, Amersi F, Are C, Arnell TD, Damewood RB, Dent DL, **Donahue T**, Gauvin J, Hartranft T, Jacobsen GR, Jarman BT, Melcher ML, Mellinger JD, Morris JB, Nehler M, Smith BR, Wolfe M, Kaji AH, de Virgilio C, “Association of General Surgery Resident Remediation and Program Director Attitudes With Resident Attrition,” *JAMA Surg* 152(12): 1134-1140, 2017.
 52. Le TM, Poddar S, Capri JR, Abt ER, Kim W, Wei L, Uong NT, Cheng CM, Braas D, Nikanjam M, Rix P, Merkurjev D, Zaretsky J, Kornblim HI, Ribas A, Herschman HR, Whitelegge J, Faull KF, **Donahue TR**, Czernin J, Radu CG, “ATR inhibition facilitates targeting of leukemia dependence on convergent nucleotide biosynthetic pathways,” *Nature Communications* 18(1): 241, 2017.
 53. Masuda T, Dann AM, Elliott IA, Baba H, Kim S, Sedarat A, Muthusamy VR, Girgis MD, Hines OJ, Reber HA, **Donahue TR**, “A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer,” *Journal of Gastrointestinal Surgery*, 22(2):295-302.
 54. Wagner JP, Lewis CE, Tillou A, Agopian VG, Quach C, **Donahue TR**, Hines OJ, “Use of Entrustable Professional Activities in the Assessment of Surgical Resident Competency,” *JAMA Surgery*. 53(4): 335-343, 2018.
 55. Elliott IA, Dann AM, Ghukasyan R, Damato L, Girgis MD, King JC, Hines OJ, Reber HA, **Donahue TR**, “Pasireotide does not prevent postoperative pancreatic fistula: a prospective study,” *HPB* 20(5): 418-422, 2018.
 56. Zettlitz KA, Tsai WK, Knowles SM, Kobayashi N, **Donahue TR**, Reiter RE, Wu AM, “Dual-modaloty immunoPET and near-infrared fluorescence (NIRF) imaging of pancreatic cancer using anti-prostate cancer stem cell antigen (PCSA) cys-diabody,” *J Nucl Med*. 2018 Mar 30.
 57. Isacoff WH, Reber HA, Bedford R, Hoos W, Rahib L, Upfill-Brown A, **Donahue T**, Hines OJ, “Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis,” *Target Oncol*, 2018, Jun 7.

B. Research Papers – Peer Reviewed (in press)

1. Koutiounpa M, Hatziapostolou M, Polytarchou C, Tolosa EJ, Almada LL, Mahurkar-Joshi S, Williams J, Tirado-Rodriguez B, Hueta-Yepe S, Karavias D, Kourea H, Poultsides GA, Struhl K, Dawson DW, **Donahue TR**, Fernandez-Zapico ME, Iliopoulos, “KMT2D histone methyltransferase acts as a tumor suppressor through metabolic reprogramming in pancreatic cancer,” *Gastroenterology*, 2018
2. Jiang J, Upfill-Brown A, Dann AM, Kim SS, Girgis MD, King JC, **Donahue TR**, “Index hospitalization length of stay and complications as predictors of readmission following open pancreaticoduodenectomy,” *JAMA Surgery*, 2018.

3. Research Papers – Peer Reviewed (Submitted)

1. Shi Y, Gao M, Peiwu H, Lytle NK, Maas A, Ridinger M, DelGiorno K, Erikson G, Sun H, Meisenhelder J, Terenziani E, Santisakultarm P, Manor U, Leblanc M, Umetsu SE, Collisson EA, Lowy AM, Reya T, **Donahue TR**, Downes M, Wahl GM, Evans RM, Pawson T, Tian R, Hunter T, “Targeting LIF1 in Pancreatic Cancer,” *Nature* 2017.
2. Nguyen AH, Dann A, Elliott IA, Toste PA, Williams JL, Li L, Wu N, Matsumura C, Kadera BE, **Donahue TR**, “Knockdown of MicroRNA-21 Suppresses the Tumor-Supportive Phenotype of Pancreatic Cancer-Associated Fibroblasts via Increased TIMP3 Expression,” *Scientific Reports*, 2017
3. Elliott EA, Dann AM, Xu S, Kim SS, Abt EA, Kim W, Poddar S, Williams JL, Capri JR, Ghukasyan R, Matsumura C, Tucker DA, Armstrong WR, Cabebe AE, Wu N, Li L, Le TM, Radu C, **Donahue TR**, “Lysosome inhibition sensitizes pancreatic cancer to replication stress by aspartate depletion,” *Proceedings of the National Academy of Sciences*, July 2018.

Research Papers (Non-Peer Reviewed)

None

Book Chapters:

1. **Donahue, T.R.**, Hines, O.J., “Distal Pancreatectomy,” *Up to Date*, Waltham, MA 02453, 2009.
2. **Donahue, T.R.**, Hines, O.J., “Distal Pancreatectomy,” *Up to Date*, Waltham, MA 02453, 2010.
3. **Donahue, T.R.**, Hiatt, J.T., “Fluids and Electrolytes,” *Current Surgical Therapy*, 10th Edition, Elsevier Saunders, Philadelphia, PA, 2011.
4. **Donahue, T.R.**, Eilber, F.C., Kattan, M.W., “Staging, Risk Stratification, Nomograms,” *Sarcoma: Diagnosis and Management (In press, 2010)*.
5. **Donahue, T.R.**, Reber, H.A., “Gallstone Pancreatitis,” *Current Surgical Therapy*, 10th Edition, Elsevier Saunders, Philadelphia, PA, 2011.
6. **Donahue, T.R.**, Reber, H.A., “Pylorus Preserving Pancreatectomy,” *Atlas of Hepatobiliary Surgery*, 1st Edition (*In press, 2010*).
7. **Donahue, T.R.**, Hines, O.J., “Distal Pancreatectomy,” *Up to Date*, Waltham, MA 02453, 2011.
8. **Donahue, T.R.**, Hiatt, J.R., “Ileus,” *Textbook of Critical Care*, 6th Edition, Elsevier Saunders, Philadelphia, PA, 2011

9. **Donahue, T.R.**, Hines, O.J., “Distal Pancreatectomy,” Up to Date, Waltham, MA 02453, 2012.
10. **Donahue, T.R.**, Reber, H.A., “Management of Patients with Severe Acute Pancreatitis,” Manigots Textbook of Abdominal Operations, 12th Edition, 2012.
11. **Donahue, T.R.**, Hines O.J., “Distal Pancreatectomy,” Up to Date, Waltham, MA 02453, 2013
12. **Donahue, T.R.**, Reber, H.A., “Management of Chronic Pancreatitis,” Current Surgical Therapy, 11th Edition, Elsevier Saunders, Philadelphia, PA, 2013.
13. **Donahue, T.R.**, Hines O.J., “Distal Pancreatectomy,” Up to Date, Waltham, MA 02453, 2014
14. **Donahue, T.R.**, Reber, H.A., “Complications of Pancreatic Surgery,” Handbook of Hepato-Pancreato-Biliary Surgery, 1st edition, Lippincott Williams & Wilkins, Philadelphia, PA, 2014.
15. Nguyen, AH, **Donahue TR**, “Pancreatitis,” Tarascon Pocket Gastropedica, *in press*, 2014
16. **Donahue, T.R.**, Hines O.J., “Distal Pancreatectomy,” Up to Date, Waltham, MA 02453, 2015
17. **Donahue, T.R.**, Hines O.J., “Distal Pancreatectomy,” Up to Date, Waltham, MA 02453, 2016
18. **Donahue, T.R.**, Hines O.J., “Distal Pancreatectomy,” Up to Date, Waltham, MA 02453, 2017

Reviews:

1. **Donahue, T.R.**, Hiatt, J.R., Busuttill, R.W., “Collagenase and Surgical Disease,” *Hernia*, 10(6): 478 – 85, 2006.
2. **Donahue, T.R.**, Hines, O.J., “CXCR2 and RET Single Nucleotide Polymorphisms and Pancreatic Cancer,” *World Journal of Surgery*, Dec., 2008.
3. **Donahue, T.R.**, Hines, O.J., “The ZIP4 Pathway in Pancreatic Cancer,” *Cancer Biology and Therapy*, 33(4): 710-5, 2009.
4. **Donahue, T.R.**, Reber, H.A., “Pancreatic Surgery,” *Current Opinion in Gastroenterology*, 26(5):499-505, 2010.
5. **Donahue, T.R.**, Reber, H.A., “Operative blood loss and survival in pancreatic cancer,” *Pancreas*, 40(1): 1-2, 2011.
6. **Donahue T.R.**, Dawson, D.W., “Nodal/Activin signaling: a novel target for pancreatic cancer stem cell therapy,” *Cell Stem Cell*, 9(5):383-4, 2011.
7. **Donahue, T.R.**, Reber, H.A., “Pancreatic Surgery,” *Current Opinion in Gastroenterology*, 29(5):522-8, 2013.
8. **Donahue, T.R.**, Reber, H.A., “Surgical Management of Pancreatic Cancer – Pancreaticoduodenectomy,” *Semin Oncol*, 42(1): 98-109, 2015
9. Stark A, **Donahue TR**, Reber HA, Hines OJ, “Pancreatic Cyst Disease: A Review,” *JAMA* 315(7):1882-93, 2016.
10. **Donahue TR**, Dawson DW, “Leveraging Mechanisms Governing Pancreatic Tumorigenesis To Reduce Pancreatic Cancer Mortality,” *Trends Endocrinol Metab.*, 27(11):770 – 781, 2016.
11. Kim SS, **Donahue TR**, “Laparoscopic Cholecystectomy,” *JAMA*, 319(17):1834, 2018.

12. Kim SS, **Donahue TR**, Girgis MD, “Carcinoembryonic Antigen for Diagnosis of Colorectal Cancer Recurrence,” *JAMA*, 320(3):298-299, 2018.

Editorials

1. **Donahue, T.R.**, “Should the duodenum be the ‘road less traveled’ for biliary reconstruction?” *JAMA Surg*, 148(9):865-6, 2013.

Case Reports:

1. Nguyen A., **Donahue T.R.**, “Metastatic pancreatic insulinoma with treatment-limiting thrombocytopenia.” *The American Surgeon*, 79(3):E124-6, 2013.
2. Vasquez CR, Chestovich P, Muthusamy VR, **Donahue TR**, “Resolution of persistent pancreaticopleural fistula after an internal drainage procedure,” *Am Surg*, 80(1):E19-21, 2014.
3. Arcega R, Wu JX, Magaki S, **Donahue TR**, Wang HL, “A hitherto undescribed benign mesenchymal polyp of the gallbladder: edematous angiomyolipoma-like polyp,” *Acta Gastroenterol Belg.*, 79(3): 245-250, 2016.
4. Sugimoto M, Hines OJ, Dawson DW, Muthusamy VR, Reber HA, **Donahue TR**, “Preoperative Treatment With FOLFIRINOX and Successful Resection for a Patient With Mixed Acinar-Endocrine Carcinoma of the Pancreas,” *Pancreas*, 46(4):e32 –e34, 2017.

Abstracts:

1. **Donahue, T.**, DiSciullo, G., Bogen, S., “L1 is Required for Lymph Node Reticular Matrix Development,” American Cancer Society Fuller Fellowship Annual Meeting (Presentation), Framingham, MA, August 1998.
2. **Donahue, T.R.**, Olson, S.Y., Economou, J.S., Garban H.J., “Celecoxib Sensitizes Human Melanoma Cells to Immune-mediated Apoptosis,” International Society for Biological Therapy of Cancer, 21st Annual Meeting (Poster), Los Angeles, CA, October 2006.
3. **Donahue, T.R.**, De La Rocha, P., Vo, D.D., Morris, L.F., Prins, R.M., Wisniewski, J., Koya, R.C., Ribas, A., Chatila, T.A., Economou, J.S., “Impact of T-Regulatory Cells on Adoptive Immunotherapy in a Lymphodepleted Murine Melanoma Model,” Society of Surgical Oncology Annual Meeting (Melanoma Parallel Session Presentation), Washington, D.C., March, 2007.
4. **Donahue, T.R.**, De La Rocha, P., Vo, D.D., Morris, L.F., Prins, R.M., Wisniewski, J., Koya, R.C., Ribas, A., Chatila, T.A., Economou, J.S., “Impact of T-Regulatory Cells on Adoptive Immunotherapy in a Lymphodepleted Murine Melanoma Model,” Longmire Scientific Day (Presentation), Department of Surgery, UCLA Medical Center, March, 2007.
5. **Donahue, T.R.**, Kattan M.W., Nelson S.D., Tap W.D., Eilber F.R., Eilber, F.C., “Impact of Neoadjuvant Treatment on Histopathologic Response and Survival in Patients with Primary High-Grade Retroperitoneal Soft Tissue Sarcomas.” American Society of Clinical Oncology (Sarcoma Parallel Session Presentation), Chicago, IL, May, 2008.
6. **Donahue, T.R.**, “Who Has the Best Resident?” USC Trauma/Critical Care Symposium, Pasadena, CA, May, 2008.

7. **Donahue, T.R.**, Kattan, M.W., Nelson, S.D., Tap, W.D., Eilber, F.R., Eilber, F.C., “Impact of Neoadjuvant Treatment on Histopathologic Response and Survival in Patients with Primary High-Grade Retroperitoneal Soft Tissue Sarcomas.” William P. Longmire Scientific Day (Presentation), Department of Surgery, UCLA Medical Center, March, 2009.
8. **Donahue, T.R.**, Kazanjian, K.K., Isacoff, W.H., Reber, H.A., Hines, O.J., “Impact of Palliative Splenectomy on Thrombocytopenia, Administration of Chemotherapy, and Survival in Patients with Unresectable Pancreatic Cancer.” Western Surgical Association Annual Meeting, San Antonio, TX, November, 2009.
9. **Donahue, T.R.**, Isacoff, W.H., Hines, O.J., Tomlinson, J.S., Farrell, J.J., Bhat, Y.M., Garon, E., Clerkin, B.M., Reber, H.A., “Downstaging chemotherapy may alter the classic CT/MRI signs of vascular involvement in patients with pancreaticobiliary cancers. This should influence patient selection for surgery.” Pacific Coast Surgical Association Annual Meeting, Maui, HI, February 16, 2010.
10. **Donahue, T.R.**, Isacoff, W.H., Hines, O.J., Tomlinson, J.S., Farrell, J.J., Bhat, Y.M., Garon, E., Clerkin, B.M., Reber, H.A., “Downstaging chemotherapy may alter the classic CT/MRI signs of vascular involvement in patients with pancreaticobiliary cancers. This should influence patient selection for surgery.” Pancreas Club Annual Meeting, New Orleans, LA, May 1, 2010.
11. **Donahue, T.R.**, Wu, N., Tran, L., Wu, X., Wong, J., Tomlinson J.S., Hines, O.J., Reber, H.A., Dawson, D.W., Wu, H., Farrell, J.J., “Pancreatic cyst fluid miRNA21 and 221 predict invasive cancer,” Pancreas Club Annual Meeting, Chicago, IL, May, 2011.
12. Wei C, Xu X, Li L, Hill R, Wu H, Dawson D, **Donahue TR**, “Integrative microRNA profiling of the human pancreatic cancer microenvironment identifies stromal miR-21 as a metastatic regulator of poor survival,” AACR/PanCAN Pancreatic Cancer: Progress and Challenges, June 21, 2012.
13. Kadera BE, Wu N, Li L, Tran L, Wu H, **Donahue TR**, “The E3 ubiquitin ligase CBL is associated with survival and mediates gemcitabine resistance in human pancreatic cancer,” American Pancreatic Association Annual Meeting, Miami, FL, November 2012.
14. Kadera BE, Li L, Wei C, Toste P, Wu N, Dawson DW, **Donahue TR**, “MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis,” American Surgical Congress, New Orleans, LA, February 2013.
15. Kadera BE, Sunjaya D, Isacoff W, Li L, Hines OJ, Dawson DW, Farrell JJ, Clerkin BM, Reber HA, **Donahue TR**, “Locally advanced pancreatic cancer: prolonged preoperative treatment is associated with lymph node negativity and excellent overall survival,” Pacific Coast Surgical Association, Kauai HI, February 2013.
16. Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, “Nonfunctional pancreatic neuroendocrine tumors < 2 cm on preoperative imaging are associated with a low incidence of nodal metastases and an excellent overall survival.” Longmire Scientific Day UCLA, Los Angeles, March, 2013.
17. Toste PA, Kadera BE, Tatishchev SF, Dawson DW, Clerkin BM, Muthusamy R, Watson R, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, “Nonfunctional pancreatic neuroendocrine tumors < 2 cm on preoperative imaging are associated

- with a low incidence of nodal metastases and an excellent overall survival.” Pancreas Club, Orlando FL, April 2013.
18. Kadera BE, Sunjaya D, Isacoff W, Li L, Hines OJ, Dawson DW, Farrell JJ, Clerkin BM, Reber HA, **Donahue TR**, “Locally advanced pancreatic cancer: prolonged preoperative treatment is associated with lymph node negativity and excellent overall survival,” Pancreas Club, Orlando FL, April 2013.
 19. Toste PA, Kadera BE, Nguyen AH, Duong M, Wu N, Li L, **Donahue TR**, “The impact of cytotoxic chemotherapy on pancreatic stellate cells,” Academic Surgical Congress, San Diego CA, February 2014.
 20. Kadera BE, Toste PA, Wu N, Li L, Dawson DW, **Donahue TR**, “Loss of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition,” Academic Surgical Congress, San Diego CA, February 2014.
 21. Toste PA, Kadera BE, Nguyen AH, Duong M, Wu N, Li L, **Donahue TR**, “The impact of cytotoxic chemotherapy on pancreatic stellate cells,” Longmire Scientific Day UCLA, Los Angeles CA, March 2014.
 22. Kadera BE, Toste PA, Wu N, Li L, Dawson DW, **Donahue TR**, “Loss of the E3 ubiquitin ligase CBL confers chemoresistance in human pancreatic cancer and is targeted by epidermal growth factor receptor inhibition,” Longmire Scientific Day UCLA, Los Angeles CA, March 2014.
 23. Toste PA, Kadera BE, Nguyen AH, Duong M, Wu N, Li L, **Donahue TR**, “The impact of cytotoxic chemotherapy on pancreatic stellate cells,” AACR Special Conference on Pancreatic Cancer, New Orleans, LA, April 2014.
 24. Nguyen AH, Patel S, Vogelauer M, Toste PA, Wu N, Williams J, Li L, Kurdistani S, **Donahue TR**, “Histone Deacetylase Inhibitors Unleash a Pro-inflammatory Phenotype in Pancreatic Cancer Fibroblasts,” Special Conference on Pancreatic Cancer, New Orleans, LA, April 2014.
 25. Nguyen AH, Toste P, Farrell JJ, Clerkin BM, Muthusamy VR, Watson R, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, “Current Indications for Surgery of Intraductal Papillary Mucinous Neoplasms May Overlook Some Patients with Cancer: Recommendations for Change,” Pancreas Club, Chicago, IL, May 2014.
 26. Toste PA, Kadera BE, Nguyen AH, Duong M, Wu N, Li L, **Donahue TR**, “The impact of cytotoxic chemotherapy on pancreatic stellate cells,” AACR Special Conference on Pancreatic Cancer, Pancreas Club, Chicago, IL, May 2014.
 27. Nguyen AH, Li L, Toste PA, Wu N, **Donahue TR**, “MicroRNAs in Pancreatic Fibroblasts Induced by Tumor Cells,” American College of Surgeons Clinical Congress, San Francisco, CA, October, 2014
 28. Nguyen AH, Patel S, Vogelauer M, Toste PA, Wu N, Williams J, Li L, Kurdistani S, **Donahue TR**, “Histone Deacetylase Inhibitors Unleash a Pro-inflammatory Phenotype in Pancreatic Cancer Fibroblasts,” American Pancreatic Association Annual Meeting, Kona HI, November, 2014
 29. Nguyen AH, Patel S, Vogelauer M, Toste PA, Wu N, Williams J, Li L, Kurdistani S, **Donahue TR**, “Histone Deacetylase Inhibitors Unleash a Pro-inflammatory Phenotype in Pancreatic Cancer Fibroblasts,” Academic Surgical Congress, Las Vegas, NV, 2015.

30. Williams JL, Nguyen AH, Wu N, Farrell JJ, Wong DS, **Donahue TR**, “Salivary microRNA Biomarker Development for Pancreatic Cancer Detection,” Canary Foundation for Earlier Diagnosis Annual Meeting, Palo Alto, CA May 2015.
31. Williams JL, Nguyen AH, Rochefort M, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, “Pancreatic Cancer Patients with Lymph Node Involvement by Direct Tumor Extension Have Similar Survival to Those with Node-Negative Disease,” Pancreas Club and Society of the Alimentary Tract, Washington DC, May 2015.
32. Williams JL, Kadera BE, Nguyen AH, Muthusamy VR, Watson R, Sedarat A, Tomlinson JS, Hines OJ, Reber HA, **Donahue TR**, “Extended Preoperative Therapy for Patients with Locally Advanced or Borderline Resectable Pancreatic Cancer Produces Excellent Survival,” American College of Surgeons Clinical Congress, Surgical Forum, Chicago IL, October 2015
33. Williams JL, Chan C, Toste PA, Gawlas IA, Vasquez CR, Sunjaya DB, Swanson E, Koo J, Hines OJ, Reber HA, Dawson DW, **Donahue TR**, “Periampullary Cancers: Histopathologic Subtype is a Stronger Determinant of Patient Survival than Anatomic Location,” Pacific Coast Surgical Association Plenary Talk, Kona, HI, 2/13/2016
34. Elliott IA, Williams JL, Ghukasyan R, Matsumura CC, Wu N, Li L, Kim W, Poddar S, Abt ER, Dann AM, DeRubertis H, Brass D, Le TM, Radu CG, **Donahue TR**, “Nucleotide Depletion by Autophagy Inhibition Sensitizes Kras-driven PDAC to Replication Stress,” Academic Surgical Congress, Las Vegas, NV, 2/2017.
35. Williams JL, Elliott IA, Nguyen AH, Matsumura C, Ghukasyan R, Toste PA, Capri JR, Patel SG, Li L, Wu N, Radu CG, **Donahue TR**, “PI3K/mTOR Inhibition Suppresses Pancreatic Cancer by Reprogramming Cancer-Associated Fibroblasts,” Academic Surgical Congress, Las Vegas, NV, 2/2017.
36. Elliott IA, Chan C, Russell T, Dann A, Williams JL, Damato LM, Chung H, Girgis MD, Hines OJ, Reber HA, **Donahue TR**, “Distinct Risk Factors for Superficial Versus Organ-space Surgical Site Infections After Pancreas Surgery,” Pacific Coast Surgical Association Plenary Talk, Palm Springs, CA, 2/2017
37. Elliott IA, Dann AM, Ghukasyan R, Damato L, Girgis MD, King JC, Hines OJ, Reber HA, **Donahue TR**, “Pasireotide does not prevent postoperative pancreatic fistula: a prospective study,” American College of Surgeons Clinical Congress, San Diego, CA, 10/2017